Deep Medicine Acquisition Corp. (DMAQ) Shareholders Approve TruGolf Deal

Deep Medicine (NASDAQ:DMAQ) announced this afternoon that its shareholders approved its combination with golf simulator company TruGolf during a special meeting on January 19.

At the meeting, holders of 3,952,979 shares of DMAQ’s Class A common stock were present, constituting a quorum. The deal was overwhelmingly approved as holders of 3,933,438 shares voted in favor of the proposal, while holders of 18,838 shares pushed back against the combination.

In connection with the vote, shareholders of 378,744 DMAQ’s public shares opted to redeem their shares. DMAQ shareholders have redeemed an aggregate of 98.5% of the trust thus far (including prior votes), leaving the SPAC with $2,254,230 and 196,020 shares remaining.

The parties did not provide a timeline for the closing of the deal, but expect to complete it upon satisfaction or waiver of all the closing conditions, including approval to list on The Nasdaq. Upon closing, the combined company is expected to trade on the Nasdaq under the symbol “TRUG”.

The SPAC also has a minimum cash condition of at least $10 million, This amount is calculated after accounting for any redemptions and payment of amounts owed to DMAQ’s sponsor and its affiliates but before settling any unpaid expenses or liabilities, with a cap of $1.6 million.

Deep Medicine announced its $125 million deal with TruGolf in April 2023. It previously planned to combine with Chinese carmaker Chijet, but the deal was terminated in September 2022. Centerville, Utah-based TruGolf manufactures advanced golf simulators and launch monitors for both home entertainment and commercial uses.